Relapse of malignancy following allogeneic hematopoietic cell transplantation (allo- 
Introduction
Adoptive immunotherapy in the form of allogeneic hematopoietic cell transplantation (allo-HCT) can cure several hematologic malignancies. However, relapse, progression or persistence of malignancy (RM) is an important cause of treatment failure and mortality following allo-HCT 1, 2 . RM may be a particularly challenging problem in patients transplanted with advanced malignancies and in patients transplanted using reducedintensity conditioning (RIC) regimens 2 . Inadequate co-stimulation of T-cells may be one mechanism underlying failure of adoptive immunotherapy following allo-HCT.
Expression of CTLA4 is induced on T-cells upon activation. It competes with
costimulatory receptor CD28 for the B7 ligands CD80 and CD86 on antigen-presenting cells. Through this and other mechanisms CTLA4 functions as an important negative regulator of the duration and intensity of antigen-specific T-cell responses 3, 4 . CTLA4 is an important mediator of peripheral self-tolerance, and tolerance to tumor antigens. Mice genetically devoid of CTLA4 develop fatal lymphoproliferation and autoimmunity 5 .
Antibody mediated blockade of CTLA4 in murine models can result in tumor regression and seems to augment the efficacy of anti-tumor vaccines 6, 7 .
Ipilimumab is a fully human IgG1 monoclonal antibody that antagonizes CTLA4
(Medarex Inc, Bloomsbury, NJ and Bristol-Myers Squibb, Wallingford, CT). Human clinical trials of this antibody in several solid tumors, especially in advanced melanoma have demonstrated regression of malignancy which can be durable [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . These responses often occur in conjunction with organ-specific auto-immune phenomena (immune For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From adverse events, IAE). Tumor regressions seen can be very delayed and may even be preceded by initial disease progression, emphasizing the immune mechanism underlying the responses seen.
T-cell replete allo-HCT relies predominantly upon antigen-specific T-cell responses to generate a graft-versus-malignancy (GVM) effect. CTLA4 blockade in this context could potentially augment the GVM effect and reverse or prevent RM. Furthermore, the existence of differences in histocompatibility antigens between donor and recipient may result in greater efficacy for this strategy than in the autologous setting. However, immune complications unique to allo-HCT, e.g. GVHD and graft-rejection may potentially also be stimulated. In a murine model of MHC disparate allogeneic transplantation, the use of an antagonistic anti-CTLA4 antibody early in the course of the transplant led to increased GVHD or graft rejection depending upon the intensity of conditioning. However, the delayed administration of the same antibody produced only limited GVHD while resulting in a powerful enhancement of the graft-versus-leukemia effect against host derived AML cells 21 .
In order to assess the efficacy of ipilimumab as a means of augmenting GVM reactions it is first important to establish a safe dose of the antibody in the setting of allo-HCT. Here we report the results of a dose-escalation trial designed to assess the safety and preliminary efficacy of ipilimumab in patients with RM following allo-HCT.
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Patients and Methods

Eligibility Criteria
All patients were > 14 years of age and had previously undergone allo-HCT from a matched sibling or matched unrelated donor for a malignant disease. Patients were eligible if they demonstrated RM more than 90 days after their last infusion of allogeneic cells ( allo-HCT or DLI) and less than three years after withdrawal of all prophylactic immunosuppression. Disease-specific criteria for RM were employed. Patients were required to have measurable or evaluable disease, except patients with acute leukemia or aggressive NHL who could be induced into a CR with conventional therapy prior to study entry. Patients were required to have > 50% donor T-cell chimerism at the time of study entry and have no ongoing clinically significant GVHD. They were required to be off all immunosuppressive medications for the treatment or prophylaxis of GVHD for > 6 weeks prior to study entry (later amended to > 4 weeks) and have no prior history of severe (grade 3 or 4) acute GVHD. Other eligibility criteria included absolute lymphocyte count > 250/mm3, ECOG PS 0-2, life expectancy > 3 months, satisfactory vital organ function unless demonstrated to be secondary to malignancy (creatinine <2.0 mg/dL, bilirubin <2.0mg/dL, AST/ALT < 3 x upper limit of normal). Patients with serious active infections, HIV, any condition requiring chronic immunosuppressive therapy, any autoimmune or second malignant condition within the last 5 years and pregnant females were excluded. Pharmacokinetics.
Blood samples were drawn immediately before the dose and at set time points thereafter.
Plasma concentrations of ipilimumab were determined by Medarex (Bloomsbury, NJ) using a quantitative enzyme-linked immunosorbent assay.
Statistical considerations.
This trial was designed as a phase I dose escalation to determine the MTD of ipilimumab administered as a single dose to patients who had previously undergone allo-HCT. A total of 15 patients were also planned to accrue at either the MTD or at 3.0mg/kg if MTD was not a lower dose. The incidence of grade DLT after ipilimumab infusion was the primary endpoint analyzed. If no DLT was observed in the 15 patients treated at this dose level, the possibility that the underlying rate of DLT was > 20% could be excluded with > 95% confidence. Median donor T-cell chimerism on day of ipilimumab infusion was 100% (range 76%-100%). Eight patients had failed prior DLI. Median time between the patient's last allogeneic cell infusion and the treatment with ipilimumab was 366 days (range 125-2368 days). Twenty-eight patients received a single infusion and one patient received two infusions (initial treatment followed by re-treatment at disease progression).
Toxicity
The adverse events experienced by the patients treated at each dose cohort are shown in Table 2 . DLT as defined was not encountered and an MTD was not reached with a single dose up to 3.0 mg/kg (one patient who developed a > grade 3 IAE did so after retreatment with ipilimumab). Although multiple grade I and 2 toxicities were recorded, no clear relationship to the study agent was evident in almost all cases. Thus 15 patients in total were treated at the originally planned highest dose (3.0 mg/kg).
GVHD
No patients developed grade 3 or 4 acute GVHD following ipilimumab alone. Three patients developed minor ocular dryness and erythema at 2 mo, 6 mo and 8 mo from a single ipilimumab infusion without subsequent DLI. They did not require systemic therapy. Two patients with pre-existing minor active chronic GVHD not requiring immunosuppressive therapy at baseline (1 oral, 1 ocular) showed no exacerbation of symptoms after ipilimumab infusion. One patient developed no GVHD after ipilimumab but developed grade 1 skin GVHD after DLI given at 2 months post ipilimumab for progressive disease.
Organ-Specific Immune Adverse Events (IAE)
Four patients developed IAE distinct from GVHD that were potentially attributable to 
Regression of Malignancy
Three patients demonstrated objective disease responses following ipilimumab alone (summarized in Table 3 ).
Patient 0414 had failed prior therapy for multiply relapsed mantle cell NHL prior to undergoing matched unrelated donor allo-HCT. Upon relapse of malignancy following allo-HCT he received two DLI without evidence of disease response. He had rapidly growing left parotid and right axillary masses prior to enrollment on study.
Administration of ipilimumab was followed approximately four weeks later with a febrile illness that was associated with significant clinical and radiologic regression of his lymphoma resulting in a PR which was persistent at 2 months following ipilimumab (Fig   2) . At 3 months following ipilimumab the responses in the parotid and axillary masses were maintained but the patient developed a new PET-avid lesion within the abdomen.
The patient was then taken off the study to pursue alternative therapeutic options.
Patient 2517 had failed a prior autologous transplant for primary refractory Hodgkin's disease before undergoing a matched related donor allo-HCT. His disease relapsed within 6 months of the transplant. He was treated with gemcitabine monotherapy followed by DLI. However, there was evidence of disease progression within two months of DLI.
The patient had evidence of PET-avid right hilar adenopathy immediately prior to receiving ipilimumab at 3.0 mg/kg. Complete remission was achieved on the one month reassessment following ipilimumab (Fig 3) . The CR has been durable for 37 months at the time of this report. The second infusion was associated with a corticosteroid-responsive non-infectious pneumonitis which progressed to grade 4 severity when the corticosteroids were tapered and discontinued (see section on IAE above). However, by 3 months following the second infusion the patient achieved a CR that was durable for 9 months thereafter. Two additional patients with Hodgkin's disease treated at the highest dose level (3.0 mg/kg) who had evidence of rapid disease progression prior to ipilimumab achieved disease stabilization for three and six months respectively following the infusion.
DLI
Nine patients received at least one DLI on study after showing persistence or progression of malignancy after ipilimumab (first DLI 0.5 x 10 7 CD3+ cells/kg; two at dose ipilimumab cohort 0.1 mg/kg, two at 0.66 mg/kg, two at 1.0mg/kg and three at 3.0mg/kg).The first DLI was administered at a median of 2 months following ipilimumab 
Pharmacokinetics
The concentration of ipilimumab at various time points following single infusion at the dose levels assessed is shown in Fig 5. All doses used achieved a peak concentration of ipilimumab > 1 μg/mL. At the highest dose studied (3.0 mg/kg), ipilimumab levels remained at concentrations above 10 μg/mL for at least 30 days and above 1 μg/mL for 60 days. have tolerated discontinuation of all immunosuppressive medications for a minimum of 4-6 weeks prior to study entry. It is unclear if ipilimumab would also not induce or exacerbate GVHD in patients who had experienced prior severe acute GVHD or those patients who were still on immunosuppressive therapy at the time of treatment. It is notable however, that several patients treated on this study had experienced some prior acute and/or chronic GVHD prior to ipilimumab therapy and all patients had at least 50% donor T-cell chimerism at the time of ipilimumab infusion (median 100%). The lack of GVHD as a complication of ipilimumab therapy in this trial cannot be explained by subtherapeutic dosing. Ipilimumab is a fully human monoclonal antibody and has a relatively prolonged half-life in vivo 8, 11, 15 . Serial estimation of serum ipilimumab concentrations in our patients demonstrated that at doses >1.0 mg/kg, serum ipilimumab levels remained above 10 μg/mL for several days (more than 30 days following a dose of 3.0 mg/kg).
Small et al observed similar levels of ipilimumab were seen following a single dose of Organ-specific IAEs were seen in four of 29 (14%) patients treated on our study. Such
IAEs have been described in trials of use of ipilimumab and another anti-CTLA4
antibody in patients with cancer who had not undergone allo-HCT [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 19, 20 . As in those reports, the IAEs seen in our study were highly responsive to immunosuppressive
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From therapy, although prolonged therapy and multiple immunosuppressive agents were required in one patient. IAEs have been found to be more common in trials using repeated dosing of ipilimumab and their occurrence is associated with regression of malignancy. Consistent with those findings, the most severe IAE in our study occurred in a patient after he was re-treated with ipilimumab. He also experienced a durable CR in his malignancy following the second infusion. The frequency of the IAEs seen in patients on our study does not appear to differ significantly from other trials where primarily a single dose of ipilimumab up to 3mg/kg has been studied. All patients treated on this study had > 50% donor T-cell chimerism at the time of ipilimumab infusion. Therefore, these data imply that despite the presence of disparity in minor-histocompatibility antigens between donor and recipient, the frequency of and severity of IAE following ipilimumab may not be significantly greater in patients following allo-HCT than in patients who have not undergone allo-HCT.
Objective responses were encountered in three patients treated on our protocol (17% of the 18 patients treated at > 1 mg/kg). The objective responses seen in our study occurred in patients with lymphoid malignancies and included two durable CRs in patients with Hodgkin's disease. This finding may be attributable to chance as HD was the most frequent malignancy treated on our study and the total number of patients with each diagnosis in our study was small. However, objective responses have been reported in patients with lymphoma 18 in a trial where the antibody was used after failure of idiotype vaccination. Further investigation of ipilimumab in patients receiving allo-HCT in HD and NHL is warranted. .Once the safety of ipilimumab following allo-HCT is fully established, its efficacy in the prophylaxis of relapse in high risk patients may be explored.
Thus, in conclusion, our study suggests that the use of ipilimumab up to 3 mg/kg as administered in our study is safe and can produce anti-tumor responses. It forms a platform for the exploration of true efficacy when used after allo-HCT through formal phase II studies in specific malignancies. Furthermore, repeated dosing and higher dosing may also now be explored as strategies to increase the efficacy of the antibody in this setting. The asterix denotes events which the investigator felt were at least possibly related to ipilimumab For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
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